605507 国邦医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,892,3572.94%5,349,4485,720,9254,505,3514,206,318
减:营业总成本2,397,2060.90%4,654,8214,664,7693,665,3913,269,523
    其中:营业成本2,123,1150.27%4,097,1194,144,8823,147,6222,775,863
               财务费用(21,099)-47.91%(46,282)(68,011)28,05481,815
               资产减值损失(44,541)161.73%(31,447)(27,706)(51,831)(14,404)
公允价值变动收益5,81259.77%10,3424,5586,25735
投资收益10,280-811.66%13,22119,5374,2763,271
    其中:对联营企业和合营企业的投资收益(453)57.78%60(745)(1,561)(1,326)
营业利润472,45913.16%702,2631,052,878808,774936,116
利润总额464,08912.40%697,6491,035,639806,782943,437
减:所得税费用59,7206.55%87,670115,017100,552133,149
净利润404,36913.31%609,979920,622706,230810,288
减:非控股权益(229)-62.74%(2,485)(282)199288
股东净利润404,59813.18%612,464920,904706,030810,000

市场价值指针
每股收益 (元) *0.73014.06%1.1001.6501.3801.710
每股派息 (元) *----0.3020.6000.700--
每股净资产 (元) *13.5475.48%13.29912.80411.3566.890
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容